A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies

RELEASE DATE
10-Nov-2014
REGION
North America
Research Code: NEC3-01-00-00-00
SKU: LS00130-NA-MR_16971
AvailableYesPDF Download

$3,950.00

Special Price $2,962.50 save 25 %

In stock
SKU
LS00130-NA-MR_16971

$3,950.00

$2,962.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.

Table of Contents

Key Findings

Recent Market Developments

Recent Market Developments (continued)

Defining Healthcare Trends in the Future

Defining Healthcare Trends in the Future (continued)

Companies to Watch

Methodology and Scope

Introduction

Market Overview—Segmentation

Market Overview—Segmentation (continued)

Market Overview—Segmentation (continued)

Prevalence of MS in Major Market

Prevalence of MS in Major Market (continued)

Physician Guidelines to MS Therapy

Competitive Landscape—Count of Marketed and Pipeline Products

MS Therapeutics Competitive Landscape

Marketed Product Analysis

Marketed Product Analysis (continued)

Pipeline Analysis—Products in Clinical Development

Pipeline Analysis—Products in Clinical Development (continued)

Pipeline Analysis—Products in Clinical Development (continued)

Pipeline Analysis—Products in Clinical Development (continued)

Pipeline Analysis—Products in Clinical Development (continued)

Pipeline Analysis—Products in Clinical Development (continued)

Pipeline Analysis—Products in Clinical Development (continued)

Product Launch Timeline

Patent Expiration Timeline

Marketed Products Clinical Program—AUBAGIO (Teriflunomide)

Marketed Products Clinical Program—Plegridy

Marketed Products Clinical Program—Tysabri

Marketed Products Clinical Program—Tecfidera

Pipeline Products Clinical Program—Ocrelizumab, Ofatumumab

Pipeline Products Clinical Program—Lemtrada

Product Dashboard—Copaxone

Product Dashboard—Avonex (interferon beta-1a)

Product Dashboard—Betaseron/Extavia (interferon beta-1b)

Product Dashboard—Rebif (interferon beta-1a)

Product Dashboard—Tysabri (natalizumab)

Product Dashboard—Gilenya

Product Dashboard—Tecfidera (oral Glatiramer Fumarate)

Product Dashboard—Aubagio (Teriflunomide)

Product Dashboard—Plegridy (BIIB017) (pegylated interferon beta-1a)

Product Dashboard—Lemtrada/Campath 1G (Alemtuzumab)

Product Dashboard—Laquinimod

Product Dashboard—Zenapax (daclizumab)

Product Dashboard—Ocrelizumab

Product Dashboard—AB1010 (Masitinib)

Product Dashboard—Ofatumumab

Conclusions and Recommendations

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.
More Information
No Index No
Podcast No
Author Aish Vivekanadan
WIP Number NEC3-01-00-00-00
Is Prebook No